Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on March 6, 2026, regarding an event dated March 5, 2026. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market under the symbol "JAGX".
Key Financial Metrics
This filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a regulatory listing matter.
Material Changes and Listing Status
On March 5, 2026, the Company received a notice from Nasdaq indicating non-compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for its common stock closed below $1.00 per share for 30 consecutive business days. Consequently, the Company is not eligible for a standard compliance period because it executed a reverse stock split within the prior one-year period (or cumulative splits of 250:1 or more within the prior two-year period).
Outlook, Risks, and Management Commentary
- Appeal Process: The Company intends to request an appeal before a Nasdaq Hearings Panel by the March 12, 2026 deadline. This request will automatically stay any delisting action pending the hearing's conclusion.
- Uncertainty: There is no assurance that the Panel will grant the request for continued listing or that the Company will regain and maintain compliance.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the appeal and potential compliance, which are subject to risks and uncertainties detailed in the Company's 2024 Form 10-K.
Investor Verification Checklist
- Verify the current stock price and whether it remains below the $1.00 threshold.
- Confirm the status of the appeal request with the Nasdaq Hearings Panel by March 12, 2026.
- Review the Company's 2024 Form 10-K for detailed risk factors and financial condition.
- Monitor for any subsequent announcements regarding the outcome of the hearing or potential delisting.